Option chain shows key data for Surrozen's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Surrozen.

Surrozen (NASDAQ:SRZN) Stock, Option Chain

Surrozen

Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

AEON

BIOR

BORR

CXAI

DOMA

DOYU

EIGR

GCTS

HGAS

HTCR

IMCC

INLX

IREN

IRON

MDIA

MESO

MMAT

NDRA

NVVE

ONDS

ORGS

OUST

PLSE

SBEV

SBFM

SGRP

SHCR

SRZN

TCOM

TPET

VSTE

ZPTA

Shares of  Nuvve Holding Corp. (NASDAQ: NVVE) fell sharply during Monday’s session after the company reported worse-than-expected fourth-quarter financial results.

Why Nuvve Holding Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

pharma lab worker ai

Biotech

Equities

Health Care

Financing

Offerings

General

Surrozen engages in a private placement, aiming to raise approximately $192.5 million in gross proceeds. Updates on SZN-043 Phase 1a trial reveal promising safety, tolerability, and effects on liver function.

Why Is Regenerative Medicine-Focused Surrozen Stock Trading Lower On Monday?

ALRM

AMRS

ATHX

ATNF

BLND

BRSH

BXSL

CARG

CLSK

CPRI

CPSI

DCTH

DNUT

EBIX

EDBL

EFXT

GDRX

GRTX

HLIT

HLLY

INVZ

LFMD

MDXH

MGNI

MGNX

MTNB

MVLA

NVAX

ORGN

ORGO

OSPN

PANL

PHXM

PLUG

RAMP

SENEA

SPRC

SSKN

STKL

Sunlight Financial Holdings, Inc. Class A Common Stock

SUNL

TASK

TAST

UIHC

VIRI

VTGN

XFOR

YELL

YETI

Gainers


	Edible Garden AG Incorporated  (NASDAQ: EDBL) shares jumped 58% to $1.88 after the company reported better-than-expected second-quarter financial results.


Why Krispy Kreme Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Surrozen Inc

The removal of the $7500 federal tax credit on the purchase of electric vehicles will effectively raise the price of Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) vehicles in the U.S. as compared to its peers and pose a huge negative catalyst for the company, The Future Fund Managing Partner Gary Black said on Tuesday. 
What Happened: While about nine Tesla vehicle models currently qualify for the tax credit, only 12 vehicles from rival brands qualify. 
Black, himself a Tesla bull, slammed bullish opinions of the removal of tax credit harming competitors over Tesla and said, &#8220;Mathematically that makes no sense, with TSLA US roughly 30-35% of TSLA global volume, and General Motors, Ford, Stellantis US EVs accounting for 4-5% of their respective global volumes.&#8221;
The removal of the tax credit will also not likely move rivals out of the EV segment, Black said. &#8220;That is the same argument I heard when TSLA cut EV prices in 2022-2023. In reality, everyone matched the TSLA-led price cuts, no one gave up, and $TSLA stock got hurt the worst in the ensuing price war,&#8221; he noted. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">2/ I keep hearing the same dumb argument that the loss of upfront EV credits hurts competition more than TSLA. Mathematically that makes no sense, with TSLA US roughly 30-35% of TSLA global volume, and <a href="https://twitter.com/search?q=%24GM&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$GM</a> <a href="https://twitter.com/search?q=%24F&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$F</a> <a href="https://twitter.com/search?q=%24STLA&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$STLA</a> <a href="https://twitter.com/search?q=%24VOW&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$VOW</a> US EVs accounting for 4-5% of their respective global…
&mdash; Gary Black (@garyblack00) <a href="https://twitter.com/garyblack00/status/1881859645515460836?ref_src=twsrc%5Etfw">January 22, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: In November, Reuters reported that&nbsp;Donald Trump‘s transition team plans to kill the $7,500 tax credit available on EV purchases. On Monday, after his inauguration, Trump himself said his administration would consider ending EV tax credits.
Currently, multiple <a href="https://www.benzinga.com/tech/25/01/43090016/here-are-the-evs-which-could-lose-7500-ev-tax-credit-under-trump-administration">Tesla vehicles qualify for a $7500 federal tax credit</a> including the single-motor and dual-motor Cybertruck, all three variants of the Model 3 and Model Y, and the all-wheel drive variant of the Model X.
Rival models that qualify for the credit include the Honda Prologue, the Cadillac Optiq, LT Model of the Chevrolet Silverado EV, among others. 
Tesla CEO Elon Musk has previously dismissed the impact of a drop in EV tax credit for Tesla saying that the impact of the elimination of subsidies&nbsp;<a href="https://www.benzinga.com/news/24/07/39934750/trump-presidency-and-ira-cut-would-be-devastating-for-competitors-says-elon-musk-long-term-probably" target="_blank" rel="noreferrer noopener">would only be slight for Tesla</a>&nbsp;but devastating for its competitors. The elimination of EV subsidies would probably help Tesla in the long term, he added.
While some other Tesla bulls also hold similar opinions, some including Black are skeptical. 
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/01/43120483/ford-mustang-architect-hal-sperlich-dies-at-95-lot-of-people-who-make-great-cars-but-so-few-who-invent-segments-like-hal-did-says-jim-farley">Ford Mustang Architect Hal Sperlich Dies At 95: &#8216;Lot Of People Who Make Great Cars But So Few Who Invent Segments Like Hal Did,&#8217; Says Jim Farley</a></li>
</ul>

TSLA

Trump's Plan To Revoke $7,500 EV Tax Credit Is A 'Huge' Negative For Tesla, Says Gary Black, Downplays Impact On Rivals

Needham analyst John Todaro maintains Riot Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) with a Buy and raises the price target from $11 to $16.

Price Target

Analyst Ratings

RIOT

Needham Maintains Buy on Riot Platforms, Raises Price Target to $16

On Tuesday, January 21st, U.S. markets closed mixed, with the S&amp;P 500 and Dow reaching month-highs as investors welcomed a restrained approach to tariffs in President Trump&#8217;s initial actions. While concerns about trade policy persist, markets were buoyed by hopes for a more strategic, negotiable approach to tariffs.
Most sectors on the S&amp;P 500 closed higher on Tuesday, with notable gains in industrials, real estate, and health care, reflecting broad market strength. However, energy stocks diverged from the overall positive trend, ending the session lower amid sector-specific pressures.
The Dow Jones Industrial Average was up 1.24% and closed at 44,025.81, the S&amp;P 500 closed higher by 0.88% at 6,049.24, and the Nasdaq Composite rose 0.64% to finish at 19,756.78.
Aisa Markets Today
<ul>
<li>On Wednesday, Japan&#8217;s Nikkei 225 closed higher by 1.58% at 39,615.50, led by gains in the Precision Instruments, Manufacturing and Textile sectors.</li>
<li>Australia&#8217;s S&amp;P/ASX 200 gained 0.33%, ending the session at 8,429.80, led by gains in the IT, Gold, and Industrials sectors.</li>
<li>India&#8217;s Nifty 50 closed higher by 0.58% at 23,159.30, while the Nifty 500 declined 0.15%, closing at 21,400.80.</li>
<li>China&#8217;s Shanghai Composite declined 0.89% and closed at 3,213.62, and the Shenzhen CSI 300 slid 0.93%, finishing the day at 3,797.02.</li>
<li>Hong Kong Hang Seng closed the session lower by 1.63% at 19,778.77.</li>
</ul>
Eurozone at 05:30 AM ET
<ul>
<li>The European STOXX 50 was up 0.83%.</li>
<li>Germany&#8217;s DAX rose 1.13%.</li>
<li>France&#8217;s CAC rose 0.77%.</li>
<li>U.K.&#8217;s FTSE index 100 traded higher by 0.24%.</li>
<li>European stocks rose modestly Wednesday amid cautious sentiment on trade threats from Trump&#8217;s administration. The focus remained on Davos, ECB rate cuts, EasyJet&#8217;s recovery, AI investments, and oil price drops due to U.S. output plans.</li>
</ul>
Commodities at 05:30 AM ET
<ul>
<li>Crude Oil WTI was trading higher by 0.58% at $76.27/bbl, and Brent was up 0.49% at $79.70/bbl.</li>
<li>Oil prices fell further Wednesday as markets reacted to Trump&#8217;s energy emergency declaration, plans to maximize U.S. production, and potential tariffs on Canada and Mexico amid mixed global demand signals.</li>
<li>Natural Gas gained 0.53% to $3.776.</li>
<li>Gold was trading higher by 0.49% at $2,772.71, Silver was up 0.42% to $31.628, and Copper fell 0.24% to $4.3305.</li>
<li>Gold prices rose to an 11-week high amid safe-haven demand driven by tariff uncertainties under Trump&#8217;s administration, while copper prices dropped on weaker demand prospects and stronger dollar concerns.</li>
</ul>
U.S. Futures at 05:30 AM ET
Dow futures were up 0.13%, S&amp;P 500 futures rose 0.40% and Nasdaq 100 futures gained 0.78%.
Forex at 05:30 AM ET
<ul>
<li>The U.S. Dollar Index declined 0.14% to 107.80, USD/JPY gained 0.14% to 155.71, and USD/AUD declined 0.26% to 1.6897.</li>
<li>The dollar hovered near two-week lows amid uncertainty over Trump&#8217;s tariff plans, with mixed currency movements reflecting cautious sentiment.</li>
</ul>
Photo by Pavel Bobrovskiy via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Commodities

Forex

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia Mixed, Europe Up As Trump's Tariff Plans Sparks Market Caution; Gold Hits 11-Week High - Global Markets Today While US Slept

Telsey Advisory Group analyst Dana Telsey maintains Levi Strauss (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) with a Outperform and maintains $26 price target.

LEVI

Telsey Advisory Group Maintains Outperform on Levi Strauss, Maintains $26 Price Target

JFBR

Jeffs' Brands announced that it has issued a non- recourse convertible promissory note in the principal amount of $2,850,000 to an institutional investor

WIIM

GE Vernova shares are trading lower after the company reported worse-than-expected Q4 EPS and revenue.

Telsey Advisory Group analyst Dana Telsey maintains VF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>) with a Market Perform and maintains $21 price target.

Telsey Advisory Group Maintains Market Perform on VF, Maintains $21 Price Target

Needham analyst Gil Blum initiates coverage on Absci (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>) with a Buy rating and announces Price Target of $9.

Initiation

ABSI

Needham Initiates Coverage On Absci with Buy Rating, Announces Price Target of $9

Guidance

Textron Sees FY25 Adj. EPS $6.00-$6.20 vs $6.42 Est.

Potter will also join the Company's Board of Directors. Potter will succeed Eric J. Lindberg, Jr., who has served as Interim President and Chief Executive Officer since October 2024.&nbsp;

Management

Grocery Outlet Holding Appoints Jason Potter As President And CEO, Effective February 3, 2025

Earnings

Earnings Misses

Textron Q4 2024 Adj. EPS $1.34, Inline, Sales $3.613B Miss $3.810B Estimate

Guidance:
GE Vernova is reaffirming its 2025 financial guidance of revenue of $36-$37 billion, high-single digits adjusted EBITDA margin&#x2A;, free cash flow&#x2A; of $2.0-$2.5 billion, and segment guidance of:&nbsp;
•Power: Mid-single digit organic revenue&#x2A; growth and 13%-14% segment EBITDA margin.
•Wind: Organic revenue&#x2A; down mid-single digits and $200-$400 million of segment EBITDA losses.
•Electrification: Mid-to-high-teens organic revenue&#x2A; growth and 11%-13% segment EBITDA margin.

GE Vernova Reaffirms FY25 Revenue Guidance Of $36B-$37B Vs. $36.88B Estimate

Oracle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) shares are trading higher premarket on Wednesday.
On Tuesday, the company disclosed new AI agents and generative AI features in Oracle Fusion Cloud Sales to enhance sales <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/n43118973/oracle-ai-agents-help-sales-teams-create-more-meaningful-customer-connections" rel="noreferrer noopener">engagement and streamline processes</a>.
These AI capabilities, integrated with Oracle Fusion Cloud Customer Experience (CX), would help sales teams streamline communication, maintain up-to-date records, and build stronger customer relationships.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/43111153/nvidia-and-ai-stock-rises-as-trump-announces-500-billion-stargate-ai-infrastructure-venture" rel="noreferrer noopener">Nvidia, AI Stocks Rise As Trump Announces $500 Billion Stargate AI Infrastructure Venture</a>
The AI-powered engagement agent generates optimized emails, while the records agent automates activity summaries and data entry.
Rob Tarkoff, executive vice president and general manager, Oracle Cloud CX said, &#8220;The new AI agents and generative AI capabilities within Oracle Cloud Sales eliminate many of these rigid and time-consuming tasks, which enables sales teams to boost productivity and create more impactful connections with customers.&#8221;
Gartner predicts that by 2026, B2B sales teams using generative AI will cut prospecting and customer-meeting prep time by over 50%.
Yesterday, co-founder&nbsp;Larry Ellison unveiled plans for an artificial intelligence-driven cancer vaccine system <a target="_blank" href="https://www.benzinga.com/markets/equities/25/01/43118941/oracles-larry-ellison-says-cancer-vaccine-tailored-in-48-hours-could-soon-be-a-reality-as-trump-announces-500-billion-ai-investment" rel="noreferrer noopener">that could deliver personalized treatments within 48 hours</a>.
The announcement came as part of a broader $500 billion AI infrastructure initiative called Stargate, a joint venture between Oracle,&nbsp;OpenAI, and&nbsp;SoftBank Group. The project will&nbsp;establish massive data centers&nbsp;across the U.S., starting with a facility in Abilene, Texas.
Investors can gain exposure to the stock via&nbsp;iShares Expanded Tech-Software Sector ETF&nbsp;(BATS:<a class="ticker" href="https://www.benzinga.com/stock/IGV#BATS">IGV</a>) and FT Vest Technology Dividend Target Income ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/TDVI#BATS">TDVI</a>).
Price Action: ORCL shares are up 9% at $188.10 premarket at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/01/43119814/google-parent-owned-startup-to-launch-ai-designed-drug-trials-by-year-end-partnering-with-eli-lilly-and-novartis-to-tackle-major-diseases" target="_blank" rel="noreferrer noopener">Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases</a></li>
</ul>
Photo via Shutterstock.

Large Cap

Tech

ORCL

TDVI

Oracle Unveils AI-Powered Sales Tools To Boost Customer Engagements: Details

Johnson & Johnson shares are trading higher after the company reported better-than-expected Q4 adjusted EPS and revenue.

Comerica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMA#NYSE">CMA</a>) reported quarterly adjusted earnings of $1.20 per share which missed the analyst consensus estimate of $1.26 by 4.76 percent. This is a 17.81 percent decrease over earnings of $1.46 per share from the same period last year. The company reported quarterly sales of $825.00 million which missed the analyst consensus estimate of $837.57 million by 1.50 percent. This is a 5.50 percent increase over sales of $782.00 million the same period last year.

Comerica Q4 Adj $1.20 Misses $1.26 Estimate, Sales $825.00M Miss $837.57M Estimate

DELL

MSFT

NVDA

Shares of AI tech companies are trading higher after President Trump announced a $500 billion AI infrastructure investment called Project Stargate.

Stifel analyst James Condulis initiates coverage on Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Buy rating and announces Price Target of $80.

CYTK

Stifel Initiates Coverage On Cytokinetics with Buy Rating, Announces Price Target of $80

GE Vernova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) reported quarterly earnings of $1.73 per share which missed the analyst consensus estimate of $2.55 by 32.16 percent. This is a 140.28 percent increase over earnings of $0.72 per share from the same period last year. The company reported quarterly sales of $10.59 billion which missed the analyst consensus estimate of $10.78 billion by 1.76 percent. This is a 8.51 percent increase over sales of $9.76 billion the same period last year.

GE Vernova Q4 2024 GAAP EPS $1.73 Misses $2.55 Estimate, Sales $10.59B Miss $10.78B Estimate

Full-year 2025 guidance:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">($ in Billions, except EPS)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">January 2025</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Adjusted Operational Sales1,2,5
Change vs. Prior Year / Mid-point
</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">2.0% – 3.0% / 2.5%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Operational Sales2,5 / Mid-point
Change vs. Prior Year / Mid-point
</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">
$90.9B – $91.7B / $91.3B
2.5% – 3.5% / 3.0%
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Estimated Reported Sales3,5/ Mid-point
Change vs. Prior Year / Mid-point
</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">
$89.2B – $90.0B / $89.6B
0.5% – 1.5% / 1.0%
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Adjusted Operational EPS (Diluted)2,4 / Mid-point
Change vs. Prior Year / Mid-point
</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">
$10.75 – $10.95 / $10.85
7.7% – 9.7% / 8.7%
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Adjusted EPS (Diluted)3,4 / Mid-point
Change vs. Prior Year / Mid-point
</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">
$10.50 – $10.70 / $10.60
5.2% – 7.2% / 6.2%
</td>
</tr>
</tbody>
</table>
</figure>

Johnson & Johnson Expects 2025 Adjusted EPS Of $10.75–$10.95 Versus Consensus Of $10.59

William Blair analyst Max Smock downgrades Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) from Outperform to Market Perform.

Downgrades

William Blair Downgrades Charles River to Market Perform

Press Releases

Surrozen Provides First Quarter 2024 Financial Results and Business Update

Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis

Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan

Surrozen Publishes Study in 'eLife' Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling

Surrozen Provides Second Quarter 2024 Financial Results and Business Update

Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration

Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis

Comments

Surrozen

Surrozen (SRZN) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga